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Background: Irritable bowel syndrome with diarrhea (IBS-D) has limited options for treat-
ment currently, including mainly anti-motility medications, antispasmodics, and antidepres-
sants. This review discusses the properties of a new drug, eluxadoline, a gut-targeting mu- and 
kappa-opioid receptor agonist and a delta-opioid receptor antagonist, and its efficacy and safety 
in patients with IBS-D.
Materials and methods: A systematic review of the literature was undertaken to identify 
studies that had investigated eluxadoline as a treatment in IBS-D. A narrative review of other 
information is provided with respect to pharmacological and chemical properties. Where suit-
able, meta-analysis was performed with a random-effects model to produce a pooled estimate.
Results: Eluxadoline showed efficacy improving stool consistency (standardized mean differ-
ence [SMD]: -0.29 at 12 weeks, p = 0.0004; -0.46 at 26 weeks, p = 0.0001), global symptoms 
(SMD: -0.15 at 12 weeks, p = 0.006; -0.14 at 26 weeks, p = 0.02), quality of life (SMD: 0.21 at 
12 weeks, p < 0.0001; 0.16 at 26 weeks, p = 0.007), pain (SMD: -0.17 at 12 weeks, p = 0.001; 
-0.16 at 26 weeks, p = 0.01), and adequate relief (odds ratio [OR]: 1.99 at 12 weeks, p < 0.00001; 
1.78 at 26 weeks, p < 0.0001). It also improved IBS severity and other abdominal symptoms 
such as bloating, discomfort, and risk of urgency and fecal incontinence. Its main side effects 
included constipation (OR: 3.49, p < 0.00001), vomiting (OR: 3.42, p = 0.0002), abdominal 
pain (OR: 1.78, p = 0.007), and nausea (OR: 1.42, p = 0.07). The overall quality of trials was 
satisfactory with the meta-analyses providing largely homogeneous outcomes.
Conclusion: Eluxadoline’s place in clinical practice might prove useful since the pharmaco-
logical options of IBS-D are limited and eluxadoline showed a positive effect in treating the 
symptoms of IBS-D.
Keywords: eluxadoline, irritable bowel syndrome, diarrhea, stool consistency, pain
Plain language summary
The current review summarizes the benefits of a new drug, eluxadoline, on the symptoms 
of irritable bowel syndrome with diarrhea in adults. Eluxadoline works on special receptors 
of the gut slowing the gut transit time. All studies comparing eluxadoline with placebo were 
searched in the scientific literature. Mathematical analysis of the available studies showed 
that patients who received eluxadoline had better stool consistency, quality of life, pain, and 
adequate relief. Patients’ irritable bowel syndrome symptoms were less and also less serious. 
Its main disadvantages were difficulty passing stools, throwing up, feeling sick, and tummy 
pain. Care should be taken and specialist advice should be sought when using eluxadoline, 
because it can interact with certain medications and should not be used on patients at risk 
of pancreatitis.
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Introduction
Recurrent abdominal pain associated with defecation or a 
change in bowel habits is considered a functional bowel dis-
order termed irritable bowel syndrome (IBS).1,2 It can present 
predominantly with diarrhea, constipation, and a mixed or 
unspecified clinical picture. IBS with diarrhea (IBS-D) is 
diagnosed when more than 25% of bowel movements pres-
ent as Bristol stool form types 6 or 7 and less than 25% of 
bowel movements present as Bristol stool form types 1 or 2 
(clinically termed diarrhea).3 Symptoms should be present 
during the last 3 months having started at least 6 months 
before diagnosis. The global prevalence of IBS is around 
11%,4 with significant morbidity since up to one-third of 
people who experience IBS symptoms will consult a physi-
cian.5–7 Among IBS diagnoses, IBS-D is the most frequent 
diagnosis (around 40%).4,8,9
IBS is considered a multifactorial disorder with an unknown 
yet pathophysiological mechanism.10,11 Significant attention has 
been given to variations in visceral hypersensitivity and gastro-
intestinal motility, with inflammation, alterations in fecal flora, 
bacterial overgrowth, food sensitivities, genetic predisposition, 
and psychosocial characteristics having been investigated as 
contributory factors.12,13 Under the biopsychosocial conceptual 
model for IBS, it is predominantly associated with impaired 
quality of life (QoL) and increased health care use.14,15
Treatment options for IBS-D are essentially few, and 
national and international bodies recommend as first-step 
dietary, lifestyle modifications, and psychological interven-
tions along with pharmacological agents, with variable suc-
cess.16 Each treatment approach tackles a different aspect 
of the pathogenetic mechanism of IBS. Pharmacologically, 
antidiarrheals (e.g., loperamide), antispasmodics (e.g., 
mebeverine and hyoscine), tricyclic antidepressants (e.g., 
amitriptyline) and selective serotonin reuptake inhibitors 
(e.g., citalopram) have been commonly used. Neomycin, 
rifaximin, probiotics, alosetron, ramosetron, and ondansetron 
have shown some effect in certain studies in IBS-D.17–19
A new drug in the treatment for patients with IBS-D is 
eluxadoline (ViberziTM, TruberziTM; Allergan Ltd, Dublin, Ire-
land). It was approved in May 2015 by the US Food and Drug 
Administration (FDA) and September 2016 by the European 
Medicines Agency (EMA) as a new agent for IBS-D20 and has 
been recommended as a possible third-line option for IBS-D by 
the National Institute for Health and Care Excellence (NICE), 
UK.21 In the current paper, we review its efficacy and safety with 
methods of systematic review and meta-analysis. First, we give 
a brief overview of eluxadoline’s market history, biochemistry, 
and pharmacology.
Eluxadoline and the gut opioid 
system
The endogenous opioid system is composed of cell sur-
face receptors (mu-opioid receptor, delta-opioid receptor, 
kappa-opioid receptor) and their endogenous ligands (beta-
endorphin, enkephalins, dynorphins).22 Opioid receptors are 
found within the enteric nervous system in the myenteric 
and submucosal plexuses, as well as muscular and immune 
cells in the stomach and intestine, in high concentrations 
influencing secretory and motor function after the release 
of the endogenous opioid peptides.23 In particular, mu-
opioid receptor agonists promote delay in gastric emptying 
and small and large intestine transit; increase pyloric tone; 
induce phasic pressure activity in the pylorus, duodenum, 
and jejunum; alter the migrating myoelectric complex; and 
cause an elevation in the resting anal sphincter pressure.19,24,25 
Hence, mu-opioid receptor agonists (e.g., morphine) promote 
constipation. Research has shown that delta-opioid receptor 
antagonists counteract this resulting constipation and increase 
the analgesia from mu-opioid receptor agonism.22,26,27
IBS-D is commonly characterized by pain and diarrhea, 
and eluxadoline was developed with a view to address both 
these symptoms.20,28 Eluxadoline is an amino acid amide with 
a molecular weight of 569.65 g/mol and a molecular formula 
of C
32
H
35
N
5
O
5
; 5-[[[(2S)-2-amino-3-[4-(aminocarbonyl)-
2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-
1H-imidazol-2yl)ethyl]amino]methyl]-2-methoxybenzoic 
acid (Figure 1).
Eluxadoline is a mu- and kappa-opioid receptor agonist 
and a delta-opioid receptor antagonist which functions in the 
gut.19,29–31 It has poor oral bioavailability and is used for its 
local effects at opiate receptors in the gastrointestinal tract.20 
Eluxadoline is a schedule IV drug in the US, subject to control 
under the Federal Controlled Substances Act of 1970, in the 
same class with tramadol and benzodiazepines.20,28
The zwitterionic nature of eluxadoline leads it to be 
negative across the gastrointestinal pH range leading to poor 
Figure 1 Chemical structure of eluxadoline.
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oral absorption (1.02%). Eluxadoline plasma concentrations 
were very low post oral administration of 100 mg tablets 
(C
max
 ~ 2–4 ng/mL, median time to C
max 
was 1.5–2 hours, 
irrespective of whether the patient was fed or fasted),20,28 and 
when given with a high-fat meal maximum plasma concen-
tration decreased by 50%. Eluxadoline is mostly excreted 
in feces (82%), and less than 1% is excreted in urine. The 
metabolism of eluxadoline involves possibly limited gluc-
uronidation forming an acyl glucuronide metabolite that 
is then excreted into urine with mean plasma elimination 
half-life ranging from 3.7 to 6 hours.32
Ex vivo and in vivo studies demonstrated that eluxado-
line in combination with a delta-opioid receptor antagonist 
reduced intestinal contractility in isolated guinea pig ileum, 
decreased neurogenically evoked secretion in mouse small 
intestine and colon compared with loperamide, and normal-
ized gut transit at 10- to 20-fold the minimum effective 
dose.24,25 Other data suggest that delta-opioid receptors play 
a role in the mechanism of action of eluxadoline possibly 
mediated through the mu-opioid and delta-opioid heteromer 
at the level of the myenteric plexus and the longitudinal 
smooth muscle.33 Regarding toxicity, no sign of central ner-
vous system effect was shown with no behavioral changes 
or signs of withdrawal in monkeys or rats.34 With regard to 
studies in human beings, as part of the drug development 
program, the abuse potential of eluxadoline compared with 
placebo and oxycodone has been tested in two studies.34 
These demonstrated that supratherapeutic doses of oral or 
intranasal eluxadoline did not result in similar effects as 
from oxycodone, which was used as a mu-agonist positive 
control, although eluxadoline was associated with euphoric 
mood in therapeutic doses.
In vitro studies did not indicate interaction of eluxado-
line with cytochrome P450 hepatic enzyme systems, and 
apart from slow glucuronide metabolite formation found in 
urine after a 1000 mg dose, eluxadoline does not seem to 
be metabolized in the liver.32,35 The potential for drug–drug 
interactions with eluxadoline is low.28 Metabolic pathways of 
eluxadoline have not been fully elucidated, and the potential 
exists for concomitant use of potent CYP inhibitors (e.g., 
bupropion, ciprofloxacin, clarithromycin, fluconazole, gem-
fibrozil, and paroxetine) to increase exposure to eluxadoline. 
As a precautionary measure, patients should be monitored 
for impairment of mental or physical abilities required for 
the performance of potentially hazardous tasks (e.g., driving 
a car and operating machinery) and for other eluxadoline-
related adverse effects.28
Eluxadoline is a substrate and inhibitor of the hepatic 
uptake transporter organic anion transport protein 1B1 
(OATP1B1),32 and its use is contraindicated in patients 
receiving potent OATP1B1 inhibitors (e.g., ciclosporin), 
where a lower dose of eluxadoline is recommended (75 mg 
twice per day). Although no dosage adjustment is needed 
when OATP1B1 substrates (e.g., rosuvastatin) are coad-
ministered with eluxadoline, caution should be exercised in 
patients receiving high doses of OATP1B1 substrates. The 
concomitant use of other medications that can cause con-
stipation, such as anticholinergics or 5-hydroxytryptamine 
(HT)
3
 antagonists, is discouraged because of eluxadoline’s 
potential additive effect.28
Eluxadoline is recommended to be taken at 100 mg 
twice daily with food or 75 mg twice daily with food if the 
patient has had a cholecystectomy, is being coadministered 
OATP1B1 inhibitors, or has mild or moderate hepatic 
impairment or cannot tolerate the higher dose.26,28,36 Contra-
indications for treatment are history of constipation, gastro-
intestinal obstruction, biliary duct obstruction, sphincter of 
Oddi dysfunction, alcohol excess, a history of pancreatitis 
or pancreatic disease, and severe hepatic impairment.26,28,36
Clinical effectiveness
Methods
The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist for systematic reviews 
and meta-analyses was followed.37 PubMed/Medline, Sco-
pus, EMBASE, and Cochrane library with no year limits 
were searched for studies. All randomized controlled trials 
involving eluxadoline in the treatment of IBS were con-
sidered. Exclusion criteria were non-randomized studies, 
pharmacological studies, and other types of articles (e.g., 
reviews, letters, and notes). The overall number of studies 
was 66 which eventually narrowed down to three randomized 
controlled trials: IBS-2001 (Phase II study),38 IBS-3001, and 
IBS-3002 (two Phase III studies; Figure 2).1,39–41 The studies 
are described in Table 1. The quality of studies (risk of bias) 
was assessed with Cochrane Collaboration’s tool.42 Rev-
Man software package (Review Manager, Version 5.2; The 
Cochrane Collaboration, Oxford, UK) was employed for sta-
tistical analyses. Dichotomous and continuous data between 
two groups were estimated with an odds ratio (OR) and the 
standardized mean difference (SMD) with two-tailed 95% CI, 
respectively. SMD values of 0.2, 0.5, and 0.8 were defined as 
small, moderate, and large effect size, respectively.43 Random-
effects meta-analysis was used throughout the current review 
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to account for heterogeneity between studies. The statistic I2 
was used to quantify the degree of heterogeneity with a score 
of 25%, 50%, and 75% representing low, moderate, and high 
levels of inconsistency, respectively. Statistical significance 
was regarded as p < 0.05 throughout the study.44
Clinical effectiveness analysis
Eluxadoline trials: IBS-2001, IBS-3001, and IBS-3002
The efficacy and safety of eluxadoline was investigated in one 
Phase II (IBS-2001)38 and two Phase III (IBS-3001 and IBS-
3002)1,39–41 randomized controlled trials. The overall number 
of subjects was 3,235 adults with IBS-D (as defined by Rome 
III criteria)45 participating in large, international, multicenter, 
placebo-controlled studies. The clinical trials were designed 
to meet a robust composite end point, defined by the FDA and 
Committee for Medicinal Products for Human Use (CHMP). 
Overall, eluxadoline provides an effective and tolerable 
treatment option in this condition albeit being considered to 
present a mild-to-moderate effect (as given in the “Methods” 
section). The outcome measures investigated included: stool 
consistency, abdominal pain, abdominal bloating, frequency 
of bowel movements, urgency of bowel movements, sever-
ity of symptoms, duration of response to treatment, adverse 
effects of treatment, and health-related QoL.
IBS-2001 was the first randomized, double-blind, con-
trolled Phase II clinical trial in which 807 patients were 
assigned to groups who received oral placebo or eluxado-
line 5, 25, 100, or 200 mg twice daily for 12 weeks.38 The 
primary end point was the number of composite clinical 
responses at week 4, defined by having completed 5-out-
of-7-days diary entries, and had an improvement by ≥30% 
and at least 2 points in average daily pain scores as well as 
a stool consistency score of 3 or 4 on the Bristol Stool Scale 
for at least 66% of daily diary entries during that week.35 
At week 4, more patients receiving treatment with 25 and 
200 mg eluxadoline met the primary end point of clinical 
response when compared with placebo (12% vs 13.8% 
vs 5.7%, respectively; p < 0.05). At week 12, this effect 
was sustained with 100 mg eluxadoline, with more clini-
cal responders compared with placebo (20.2% vs 11.3%, 
respectively; p < 0.05). At week 4, there was a statistically 
significant increase in the number of stool consistency 
responders in those taking 25 and 200 mg eluxadoline 
when compared with placebo (16.8% vs 18.1% vs 8.2%, 
respectively; p < 0.05).
Although 200 mg eluxadoline had achieved a significant 
decrease in IBS Global Symptom Scores compared with 
placebo by week 4, which was sustained at weeks 8 and 12 
Figure 2 Flowchart of studies.
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(-0.26, -0.30, -0.34, respectively; p < 0.001), 100 mg elux-
adoline achieved a similar effect in weeks 8 and 12 (-0.19, 
-0.26, respectively; p < 0.05). Similarly, mean differences 
in IBS Symptom Severity Scores from placebo were statisti-
cally significant for the 100 mg eluxadoline group at the end 
of weeks 4, 8, and 12 (-16.69, -33.55, -50.40, respectively; 
p < 0.05) and for the 200 mg eluxadoline group at weeks 8 
and 12 (-19.89, -27.48, respectively; p < 0.05). A greater 
improvement in QoL (IBS-QoL total score) was observed for 
patients receiving treatment with 100 and 200 mg eluxadoline 
when compared with placebo at the end of weeks 4, 8, and 12. 
Adequate relief was achieved in more patients who received 
Table 1 Randomized controlled trials of eluxadoline for IBS-D
Design Number of 
participants
Primary and secondary end points Dose and duration Inclusion criteria
IBS-2001: 
randomized, 
double-blind, 
placebo-controlled, 
multicenter study38
•	 Total: 807
•	 Eluxadoline: 635
•	 Placebo: 172
•	 Primary outcome: number of 
composite clinical responses at 
week 4. A patient was defined as a 
clinical responder if they completed 
5-out-of-7-days of diary entries and 
met both of the following criteria: an 
improvement by ≥30% and at least 
2 points in average daily pain scores as 
compared with baseline and achieved 
a Bristol Stool Scale score of 3 or 
4 on >66% of reported days in the 
past week
•	 Secondary outcomes: composite 
clinical responders after 12 weeks; 
abdominal pain responders, stool 
consistency responders, adequate 
relief responders, frequency of 
bowel movements; urgency episodes, 
incontinence episodes, changes in IBS 
global symptoms, QoL, and severity 
scores
Eluxadoline: 5 or 25 
or 100 or 200 mg 
twice per day by 
mouth vs placebo 
twice per day for 
12 weeks
•	 Age: 18–65 years old
•	 IBS-D defined by Rome III 
criteria
•	 Average of daily pain scores of 
≥3.0 on a 0–10-point scale
•	 Weekly mean Bristol Stool Scale 
score equal to or over 5.5
•	 Colonoscopy within the past 
5 years for any alarm feature
•	 Stable diet and no use of rescue 
medication within 14 days of 
randomization
•	 Female patients: postmenopausal 
or surgically sterile or abstinent 
or receiving contraception, if 
sexually active
IBS-3001, IBS-
3002: prospective, 
double-blind 
placebo-controlled, 
multicenter 
studies1,39–41
•	 Total: 2428
•	 Eluxadoline: 1616
•	 Placebo: 809
•	 Primary outcome: number of 
composite clinical responders over 
26 weeks. Clinical responder: if they 
met the daily response criteria for 
at least half of the days with diary 
entries. On a given day, both of the 
below should be satisfied: daily pain 
response (worst abdominal pain 
scores in the past 24 hours improved 
by ≥30% compared with baseline) 
and daily stool consistency response 
(Bristol Stool Scale score < 5 or the 
absence of a bowel movement if 
accompanied by ≥30% improvement in 
worst abdominal pain compared with 
baseline pain).
•	 Secondary outcomes: abdominal pain 
responders defined as those patients 
who met the daily pain response 
criteria; stool consistency responders, 
adequate relief responders, frequency 
of bowel movements; urgency 
episodes, incontinence episodes, 
changes in IBS global symptoms, and 
QoL
Eluxadoline: 75 or 
100 mg twice per day 
by mouth vs placebo 
twice per day for 
26 weeks
•	 Age: 18–80 years old
•	 IBS-D defined by Rome III 
criteria
•	 Average of worst abdominal pain 
scores of ≥3.0 on a 0–10-point 
scale
•	 Average mean Bristol Stool 
Scale of ≥5.5 and at least 5 days 
with a Bristol Stool Consistency 
Scale score ≥5 on a 1–7-point 
scale
•	 Average daily IBS-D Global 
Symptom Score of ≥2.0 on a 
0–4-point scale
•	 Stable diet and no use of rescue 
medication within 14 days of 
randomization
•	 Female patients: postmenopausal 
or surgically sterile or abstinent 
or receiving contraception, if 
sexually active
Abbreviations: IBS-D, irritable bowel syndrome with diarrhea; QoL, quality of life.
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treatment with 100 or 200 mg eluxadoline at weeks 4, 8, and 
12 (69.3%/67.4%, 74.9%/71.5%, 79.7%/75.4%, respectively; 
p < 0.05), and at week 8 in those receiving 25 mg eluxadoline 
when compared with placebo (64.2% vs 56.8%). Over the 
entire study duration, there was a statistically significant 
increase in the percentage of adequate relief responders in 
the 100 and 200 mg groups (63.5% and 59.3%, respectively) 
when compared with placebo (46.4%; p < 0.05).
Phase III studies included patients who received eluxado-
line 100 or 75 mg twice daily, since the 200 mg twice-daily 
dose did not provide better risk–benefit ratio over the 100 mg 
dose.38 IBS-3001 and IBS-3002 were reported in four papers, 
inclusive of a pooled analysis.1,39–41 They are randomized, 
double-blind, placebo-controlled, parallel-group, multicenter 
studies involving overall 2,427 subjects being randomized to 
compare eluxadoline 75 or 100 mg twice daily and placebo. 
IBS-3001 was approximately 58 weeks, and IBS-3002 was 
approximately 34 weeks. A composite clinical response, 
defined as decrease in daily worst abdominal pain and 
Bristol Stool Scale scores over 26 weeks, was evaluated.25 
A patient was defined as a clinical responder if they met 
the daily response criteria for at least 50% of the days with 
diary entries. Treatment with 100 mg eluxadoline resulted 
in an absolute 9.1–13.7%-point increase in the proportion 
of patients achieving the composite primary end point when 
compared with placebo.21 In both IBS-3001 and IBS-3002, a 
significantly greater proportion of patients receiving 100 mg 
eluxadoline met the primary end point of clinical response 
compared with placebo at week 26 (29.3% vs 20.2% and 
32.7% vs 19.0%, respectively, p ≤ 0.001). In IBS-3002, a 
significantly greater proportion of patients receiving 75 mg 
eluxadoline achieved a composite response compared with 
placebo (30.4% vs 20.2%, respectively, p < 0.05). A similar 
composite response was found in the pooled analysis with 
the treatment benefit of eluxadoline over placebo being 
maintained throughout weeks 1–26.1 At week 26, there 
were significantly more adequate relief responders in those 
patients receiving 100 mg eluxadoline in both IBS-3001 and 
IBS-3002 when compared with placebo (49.5% vs 40.0% 
and 53.7% vs 43.7%, respectively, p < 0.01), with a similar 
pattern in the pooled analysis (p < 0.05), while IBS-3002 
showed an effect for 75 mg eluxadoline as well, compared 
with placebo (52.8% vs 43.7%, respectively, p = 0.013). In 
IBS-3001, IBS-3002, and the pooled analysis, there was a 
significant increase in stool consistency responders in patients 
receiving 100 mg eluxadoline throughout weeks 1–26 (34.0% 
vs 24.1%, 39.8% vs 23.6%, 36.8% vs 23.9%, respectively, 
p ≤ 0.001). IBS-3002 showed a significant effect of 75 mg 
eluxadoline compared with placebo as well in stool consis-
tency responders (34.4% vs 23.6%, p < 0.001).
In IBS-3001 and IBS-3002, there was no significant differ-
ence in the proportion of pain responders at 12 and 26 weeks 
in either eluxadoline groups vs placebo. The pooled analysis 
however managed to show an effect on pain in the 100 mg 
eluxadoline group vs placebo (p < 0.05), albeit the criteria 
were slightly more strict. IBS-QoL scores were generally 
higher in patients receiving 75 or 100 mg eluxadoline when 
compared with placebo from both studies and their pooled 
analysis. In a longitudinal analysis, scores were significantly 
higher than placebo for both eluxadoline treatment groups at 
each visit in IBS-3001 and in the 75 mg group in IBS-3002, 
while statistical differences were observed at 4, 8, 12, and 
18 weeks in the 100 mg group in IBS-3002. In the pooled 
analysis, IBS-QoL total scores were significantly greater 
than placebo at week 26 for both the 75 and 100 mg treat-
ment groups (p < 0.001). Finally, significant improvements 
were observed in abdominal bloating, abdominal discomfort, 
frequency of bowel movements, risk of urgency episodes, and 
risk of incontinence episodes in patients receiving treatment 
with eluxadoline compared with placebo.
Meta-analysis
Meta-analysis was performed on five outcomes at two time 
points, 12 weeks and 26 weeks: Bristol Stool Scale consis-
tency score, Daily Pain Score, IBS-QoL Total Score, Global 
Symptom Score, and Adequate Relief of IBS Symptoms. 
The effects of eluxadoline are statistically significant for all 
outcomes in favor of eluxadoline, albeit a small-to-moderate 
effect. There was heterogeneity in the Bristol Stool Scale con-
sistency at 12 weeks and the IBS-QoL at 26 weeks (Table 2 
and Figure 3). Quality assessment was satisfactory with no 
bias present (Figure 4).
Safety and adverse events
Frequency of any adverse events ranged from 43.8% to 60.2% 
in all trials. Serious adverse events were between 3.0% and 
4.8%, and no deaths were reported during the study. The 
frequency of adverse events was largely equal between pla-
cebo and treatment (Figure 5). Overall, eluxadoline was well 
tolerated with the most common adverse events being nausea, 
constipation, vomiting, and abdominal pain seen in patients 
with IBS-D (frequency less than 10%). The rate of discontinu-
ation due to constipation and nausea was small and ranged 
between 0.6% and 1.7% for eluxadoline. Five (0.3%) patients 
receiving eluxadoline developed pancreatitis, and there were 
eight (0.5%) cases of abdominal pain with elevated levels of 
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hepatic enzymes in IBS-3001 and IBS-3002. Eight of the 13 
cases were associated with spasm in the sphincter of Oddi 
(0.5%). All cases were associated with prior cholecystectomy, 
and seven cases occurred within 2 weeks of initiated study 
drug.21 Other adverse events are summarized in Table 3. There 
was no evidence to suggest biochemical derangement, worsen-
ing of IBS symptoms or opioid withdrawal.1,38–41
Random-effects meta-analysis of the adverse events 
indicated that constipation and vomiting were up to 3.5 times 
more likely to occur with eluxadoline 100 mg compared 
with placebo. Nausea and abdominal pain were 42% and 
78%, respectively, more likely to occur with eluxadoline 
100 mg compared with placebo. Constipation, vomiting, 
and abdominal pain were significantly higher in the 100 mg 
eluxadoline group compared with placebo whilst adverse 
events overall and nausea were not. Significant heterogeneity 
was not present in any adverse event analyzed.
Discussion and conclusion
The current review looked at the characteristics of eluxado-
line, a gut-targeting mu- and kappa-opioid receptor agonist 
and a delta-opioid receptor antagonist, and the clinical trials 
that investigated its efficacy and safety in IBS-D. Overall, 
eluxadoline is a new molecule with attractive characteris-
tics for the patients with IBS-D, having shown efficacy in 
 improving stool consistency, global symptoms, IBS severity, 
QoL, pain, and adequate relief. Its main side effects include 
nausea, vomiting, constipation, and abdominal pain. Precau-
tions should be taken when using it with respect to interaction 
with certain class of drugs and patients at risk of sphincter 
of Oddi spasm leading to pancreatitis. The overall quality of 
trials is satisfactory with the meta-analyses providing largely 
homogeneous outcomes.
Its place in clinical practice might prove useful since the 
pharmacological options of IBS-D are limited to loperamide, 
antispasmodics, and antidepressants. Less commonly used 
are 5-HT
3
 receptor antagonists,46 or rifaximin.47 The evidence 
for antidepressants in IBS-D is limited,48 while for loperamide 
or antispasmodics clinical experience is existent and acces-
sibility to them is eased by low cost and over-the-counter 
purchasing. Clinical use will show whether eluxadoline might 
prove a suitable second-line treatment for IBS-D instead 
of antidepressants, or if it will function preferably as third 
line. A recent NICE UK technology review suggests that 
eluxadoline can be considered a cost-effective treatment for 
patients with IBS-D who have not responded adequately to 
or cannot tolerate other suitable pharmacological therapies.21
The current emerging treatments for IBS-D are rifaximin 
and selective 5-HT3 receptors along with existing first-line 
treatments such as antispasmodics, loperamide, tricyclic 
Table 2 Meta-analysis of efficacy outcomes and main adverse events
Outcome Studies Participants Effect estimate (95% CI) Heterogeneity: I2 (%)
Efficacy outcomes
Bristol Stool Scale consistency score
12 weeksa 3 1524 SMD: -0.29 (-0.45, -0.13) 56
26 weeksa 2 1057 SMD: -0.42 (-0.64, -0.20) 67
Daily Pain Score
12 weeksa 3 1529 SMD: -0.17 (-0.27, -0.07) 0
26 weeksa 2 1060 SMD: -0.16 (-0.28, -0.04) 0
IBS-QoL Total Score
12 weeksa 3 1581 SMD: 0.21 (0.11, 0.31) 10
26 weeksa 2 1128 SMD: 0.16 (0.04, 0.27) 31
Global Symptom Score
12 weeksa 2 1287 SMD: -0.15 (-0.27, -0.04) 0
26 weeksa 2 1060 SMD: -0.14 (-0.27, -0.02) 0
Adequate Relief of IBS Symptoms
12 weeksb 3 913 OR: 1.99 (1.61, 2.45) 2
26 weeksb 2 1060 OR: 1.78 (1.35, 2.35) 0
Adverse events
All adverse eventsc 2 1991 OR: 1.02 (0.79, 1.32) 32
Constipationc 2 1991 OR: 3.49 (2.20, 5.55) 0
Vomitingc 2 1991 OR: 3.42 (1.79, 6.54) 0
Abdominal painc 2 1991 OR: 1.78 (1.17, 2.70) 0
Nauseac 2 1937 OR: 1.42 (0.97, 2.07) 0
Notes: aSMD (inverse variance random effects). bOR (inverse variance random effects). cOR (Mantel–Haenszel random effects).
Abbreviations: IBS, irritable bowel syndrome; OR, odds ratio; QoL, quality of life; SMD, standardized mean difference.
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Figure 3 Forest plots of efficacy outcomes.
Note: Eluxadoline vs placebo at 12 and 26 weeks.
Abbreviations: IBS, irritable bowel syndrome; IV,  inverse variance; OR, odds ratio; QoL, quality of life; SE, standard error; SMD, standardized mean difference.
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Figure 4 Risk of bias graph: review authors’ judgments about each risk of bias item presented as percentages across all included studies.
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Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Low risk of bias Unclear risk of bias High risk of bias
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Figure 5 Forest plots of adverse events.
Note: Eluxadoline 100 mg vs placebo.
Abbreviations: M-H, Mantel–Haenszel; OR, odds ratio.
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antidepressants, and selective serotonin reuptake inhibitors. 
A statistical comparison of the outcomes for eluxadoline 
against other treatments is not possible without a network 
meta-analysis, but a narrative comparison can provide some 
insight. It has been reported that the number needed to 
treat for selective serotonin reuptake inhibitors or tricyclic 
antidepressants was four in IBS-D,49,50 which is lower than 
the number needed to treat for eluxadoline from the current 
review (9 [95% CI: 7–13] at 12 weeks, 17 [95% CI: 11–32] at 
26 weeks to achieve adequate relief). Rifaximin is the antibi-
otic mostly evaluated in studies with patients with IBS. It is an 
oral, non-absorbable, broad-spectrum antibiotic targeting gut 
flora and has been  shown to relieve IBS symptoms, bloating, 
abdominal pain, and loose or watery stools better than the 
placebo for up to 10 weeks after completion of therapy with 
repeat courses not hindering its durability.51 Alosetron and 
ondansetron as selective 5-HT3 receptors have also shown 
promise in improving stool consistency, improving pain 
(mainly alosetron), and prolonging gut transit. Compared 
with eluxadoline, durability was one aspect that was not 
maintained and declined at 26 weeks while gut transit was 
not examined or reported in eluxadoline studies.
Despite the statistical significance of the current review’s 
results, caution should be exercised as to how to extrapolate 
these results to clinically meaningful improvements. The 
SMDs for pain, QoL, global symptoms score, and stool con-
sistency were generally low to moderate. The most relevant 
clinical figure of the results is the OR for adequate relief which 
indicated that almost twice as many responders were in the 
eluxadoline group, reflecting the numbers needed to treat men-
tioned earlier. What is apparent is that eluxadoline’s response 
over time declines with regard to almost all symptoms (pain, 
stool consistency, global symptoms, and adequate relief).
Next, the side effects of eluxadoline are an additional 
reason that support its use as a third-line treatment. Con-
sidering the increased frequency of cholecystectomies in 
populations,52,53 the prospect of acute pancreatitis with con-
sequent hospitalizations is very serious and could deter use. 
Furthermore, the presence of side effects such as constipation 
or nausea might well be considered as bad as the original 
symptoms of IBS-D. Patients might have increased visceral 
hypersensitivity, and in the context of having failed other 
treatments already they might be apprehensive trying further 
medications if they know the high possibility of side effects.
Table 3 Frequency of adverse events for IBS-2001, IBS-3001, and IBS-3002
Adverse events Pooled analysis of IBS-3001 and IBS-3002 IBS-2001
Eluxadoline Placebo  
(n = 808)
Eluxadoline Placebo  
(n = 159)75 mg  
(n = 807)
100 mg  
(n = 859)
Combined  
groups  
(n = 1,666)
5 mg  
(n = 105)
25 mg  
(n = 170)
100 mg  
(n = 165)
200 mg  
(n = 172)
All adverse events 486 (60.2)a 500 (58.2) 986 (59.2) 450 (55.7) 46 (43.8) 86 (50.6) 73 (44.2) 90 (52.3) 78 (49.1)
Serious adverse events 34 (4.2) 41 (4.8) 75 (4.5) 24 (3.0)
Cardiac events 12 (1.5) 17 (2.0) 75 (4.5) 8 (1.0)
Pancreatitis 2 (0.2) 3 (0.3) 5 (0.3) 0 (0.0)
Spasm of the sphincter of 
Oddi
1 (0.1) 7 (0.8) 8 (0.5) 0 (0.0)
Constipation 60 (7.4) 74 (8.6) 134 (8.0) 20 (2.5) 2 (1.9) 5 (2.9) 10 (6.1) 6 (3.5) 4 (2.5)
Nausea 65 (8.1) 64 (7.5) 129 (7.7) 41 (5.1) 6 (5.7) 11 (6.5) 9 (5.5) 18 (10.5) 7 (4.4)
Abdominal pain 47 (5.8) 62 (7.2) 109 (6.5) 33 (4.1) 3 (2.9) 6 (3.5) 4 (2.4) 13 (7.6) 3 (1.9)
Vomiting 32 (4.0) 36 (4.2) 68 (4.1) 11 (1.4) 1 (1.0) 7 (4.1) 7 (4.2) 12 (7.0) 1 (0.6)
Abdominal distension 21 (2.6) 22 (2.6) 43 (2.6) 13 (1.6) 0 (0.0) 0 (0.0) 6 (3.6) 1 (0.6) 2 (1.3)
Gastroenteritis 36 (4.5) 19 (2.2) 55 (3.3) 27 (3.3)
Flatulence 21 (2.6) 27 (3.1) 48 (2.9) 13 (1.6)
Upper respiratory tract 
infection
27 (3.3) 47 (5.5) 74 (4.4) 32 (4.0)
Bronchitis 26 (3.2) 27 (3.1) 53 (3.2) 18 (2.2) 4 (3.8) 4 (2.4) 3 (1.8) 1 (0.6) 3 (1.9)
Sinusitis 27 (3.3) 24 (2.8) 51 (3.1) 26 (3.2) 5 (4.8) 4 (2.4) 3 (1.8) 1 (0.6) 9 (5.7)
Nasopharyngitis 33 (4.1) 23 (2,7) 56 (3.4) 27 (3.3) 4 (3.8) 8 (4.7) 7 (4.2) 6 (3.5) 6 (3.8)
Dizziness 21 (2.6) 28 (3.3) 49 (2.9) 17 (2.1)
Anxiety 10 (1.2) 19 (2.2) 29 (1.7) 14 (1.7)
Increased level of alanine 
aminotransferase
17 (2.1) 26 (3.0) 43 (2.6) 12 (1.5)
Note: aNumber of patients (%).
Abbreviation: IBS, irritable bowel syndrome.
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A final point that needs to be considered is the potential 
for opioid abuse with eluxadoline as a mu- and kappa-
opioid receptor agonist. This was shown with the presence 
of euphoric mood, drunkenness, or sedation, as an adverse 
event and the general recommendation that patients need to 
be monitored for their ability to drive a car when on treat-
ment. No other central nervous system side effects were noted 
outside these events. The data so far however allow a reserved 
view of eluxadoline as a drug with a low potential for abuse 
and low risk of dependence, with the US Drug Enforcement 
Administration (DEA) having ruled that eluxadoline be 
placed into Schedule IV of the Controlled Substances Act. 
This is due to the fact that adverse events of euphoric mood 
were observed with both oral and intranasal eluxadoline at 
a much lower frequency compared with oxycodone, similar 
rates of euphoric mood were noted with eluxadoline and 
placebo and there was also no evidence of opioid withdrawal 
after discontinuation of eluxadoline. Similarly, the peripheral 
mu-opioid receptor agonist loperamide showed evidence of 
limited abuse potential in clinical studies and is not a drug 
of abuse.54 The potential for abuse could stem from the 
delta-receptor selective antagonism as has been exhibited in 
mice.34,55,56 Pharmacovigilance with prospective follow-up 
of self-administration or human trials will be required to 
determine whether eluxadoline is in fact subject to abuse.
In conclusion, considering its affinity to mu-opioid recep-
tors, it is interesting to see whether eluxadoline’s use will 
be investigated in other cases of functional diarrhea such as 
diabetic diarrhea, opioid withdrawal-induced diarrhea, fecal 
incontinence, or even high ostomy outputs. The potential 
for abuse needs to be carefully monitored by clinicians and 
the pharmaceutical industry. Nevertheless, eluxadoline will 
hopefully prove successful in filling the treatment gap cur-
rently present in IBS-D.
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